CSIMarket
 



Regeneron Pharmaceuticals Inc   (REGN)
Other Ticker:  
 
 



 

What are Regeneron Pharmaceuticals Inc's Business Segments?



Regeneron Pharmaceuticals Inc is a biotechnology company that specializes in the discovery, development, and commercialization of innovative medicines for the treatment of serious diseases. The company has a diverse range of segments, products, and services that cater to different therapeutic areas.

Segments:
Regeneron Pharmaceuticals Inc has different segments, which include:

1. EYLEA (aflibercept) injection: EYLEA is a vascular endothelial growth factor (VEGF) inhibitor used for the treatment of certain eye diseases, such as wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.

2. Dupixent (dupilumab): Dupixent is a human monoclonal antibody used for the treatment of moderate-to-severe atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.

3. Oncology: Regeneron Pharmaceuticals Inc is developing a pipeline of potential cancer treatments, which includes the investigational anti-BCMA bispecific antibody candidate REGN5458, and the investigational anti-LAG-3 antibody candidate REGN376

4. Neurology: Regeneron Pharmaceuticals Inc is developing a pipeline of potential treatments for neurological disorders and diseases, which includes the investigational anti-amyloid beta monoclonal antibody candidate REGN2477, and the investigational anti-Tau monoclonal antibody candidate REGN2810.

5. Infectious Diseases: Regeneron Pharmaceuticals Inc is developing a pipeline of potential treatments for infectious diseases, which includes the investigational monoclonal antibody cocktail for COVID-19 treatment called REGEN-COV.

Products and Services:
Regeneron Pharmaceuticals Inc has a wide range of products and services that cater to different therapeutic areas, including:

1. Discovery Research: Regeneron Pharmaceuticals Inc has a proprietary technology platform called VelociGene, which is used for the rapid generation of genetically modified mice. The company also has a unique human genetics program called the Regeneron Genetics Center, which is a collaboration with academic institutions and healthcare systems to sequence and analyze genetic data.

2. Drug Development: Regeneron Pharmaceuticals Inc has a robust pipeline of potential treatments for a variety of diseases and disorders, including ophthalmology, neurology, infectious diseases, oncology, and inflammation. The company uses advanced technologies and scientific know-how to develop new treatments.

3. Manufacturing: Regeneron Pharmaceuticals Inc operates a state-of-the-art manufacturing facility in New York, which produces large-scale quantities of its biologic products, such as EYLEA and Dupixent.

4. Commercialization: Regeneron Pharmaceuticals Inc has a dedicated global commercial team that is responsible for the marketing and sales of its products in different countries around the world.

In conclusion, Regeneron Pharmaceuticals Inc offers a broad range of segments, products, and services that cater to different therapeutic areas, including ophthalmology, neurology, infectious diseases, oncology, and inflammation. The company's mission is to use science and technology to develop innovative medicines that can make a meaningful difference in patients' lives.
   

Regeneron Pharmaceuticals Inc Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q4
Revenues
(in millions $)
Q4
Income
(in millions $)
(Dec 31 2023)
%
(Profit Margin)
Total 3,434.30 1,159.60 33.77 %

Growth rates by Segment Q4
Y/Y Revenue
%
(Dec 31 2023)
Q/Q Revenue
%
Q4
Y/Y Income
%
(Dec 31 2023)
Q/Q Income
%
Total 0.58 % 2.13 % -3.13 % 15.06 %

To get more information on Regeneron Pharmaceuticals Inc's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com